pteridines has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 2 studies
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In most patients with chronic myeloid leukemia (CML), the disease can be kept under control using the BCR/ABL kinase inhibitor imatinib." | 1.36 | Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. ( Cerny-Reiterer, S; Ferenc, V; Gleixner, KV; Gruze, A; Hadzijusufovic, E; Mayerhofer, M; Meyer, RA; Peter, B; Pickl, WF; Sillaber, C; Valent, P, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mancini, M | 1 |
| De Santis, S | 1 |
| Monaldi, C | 1 |
| Bavaro, L | 1 |
| Martelli, M | 1 |
| Castagnetti, F | 1 |
| Gugliotta, G | 1 |
| Rosti, G | 1 |
| Santucci, MA | 1 |
| Martinelli, G | 1 |
| Cavo, M | 1 |
| Soverini, S | 1 |
| Gleixner, KV | 1 |
| Ferenc, V | 1 |
| Peter, B | 1 |
| Gruze, A | 1 |
| Meyer, RA | 1 |
| Hadzijusufovic, E | 1 |
| Cerny-Reiterer, S | 1 |
| Mayerhofer, M | 1 |
| Pickl, WF | 1 |
| Sillaber, C | 1 |
| Valent, P | 1 |
2 other studies available for pteridines and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
Topics: Aurora Kinase A; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Forkh | 2019 |
Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Cycle Prot | 2010 |